tbuckley/cabot-search huggingface dataset:
Cost effectiveness of intravenous (IV) zoledronic acid vs other IV bisphosphonates for the prevention of bone complications in breast cancer patients with bone metastases: A Markov model from the UK perspective
Authors: M. F. Botteman, M. S. Aapro, J. W. Hay, J. M. Stephens, J. Brandman
Journal: Journal of Clinical Oncology (2005)

721 Background: IV bisphosphonate agents are effective in reducing skeletal related events (SREs) and alleviating bone pain in breast cancer patients with bone metastasis. However, these agents are characterized by different efficacy, administration time, and costs. We conducted an economic analysis to compare cost-effectiveness of these agents from the UK NHS perspective. Methods: A Markov model was developed to simulate survival and incidence of SREs for a hypothetical cohort of patients receiving no treatment (NT) or monthly injections of ibandronate (IBN), generic pamidronate (PA) or zoledronic acid (ZA). Probabilities of SREs (extrapolated from skeletal morbidity rates [SMR]) and mortality data were obtained from published clinical trials of each agent. Costs of drugs and their infusion, cost of SREs, and utility values were estimated from published sources. Utilities were applied to time with and without SREs to capture the impact on quality of life. Results: Based on relative reduction of risk of SREs (ratio of SMR of bisphosphonate therapy vs no therapy), the cumulative number of SREs over the lifetime of the patients was lowest for ZA (3.82 per patient), followed by PA (4.43), IBN (4.89), and NT (6.02). Total discounted costs (which included drug costs, infusion administration costs, and cost of treating SREs) were £2457 per patient lower for ZA than IBN, £1160 per patient than PA, and £556 per patient lower than NT. Survival was identical across all groups (25 months). However, discounted quality-adjusted life-years per patient was highest with ZA (0.822), followed by PA (0.816), IBN (0.812), and NT (0.773). ZA was less costly and more effective than all other therapies, and is therefore the economically preferred option. These findings were robust across various sensitivity analyses. Conclusions: Zoledronic acid appears to be the most cost-effective IV bisphosphonate therapy and is also highly cost effective compared to no therapy. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Novartis, Roche Novartis, Roche Novartis, Roche
Management of interpersonal issues in systematic desensitization
Authors: D L Braff, M Raskin, D Geisinger
Journal: American Journal of Psychiatry (1976)

The authors use the management of typical clinical problems that arise during systematic desensitization as a model for the analysis and solution of problems associated with behavior therapy techniques. Three main problem areas are considered: initiation of the technique, therapist and patient difficulties, and therapeutic decision making. The discussion is designed primarily to help therapists with varied backgrounds to deal with clinical issues that arise in the application of behavior therapy techniques such as systematic desensitization.
PTU-164 Factors associated with morbidity following sacral neurostimulation for faecal incontinence: beware of the high risk groups
Authors: A Cracco, S Chadi, FG Rodrigues, M Zutshi, B Gurland, SD Wexner, G Dasilva
Journal: Gut (2015)

<h3>Introduction</h3> Sacral Neurostimulation (SNS) has become a preferred treatment for faecal incontinence (FI). The aim of this study was to identify the factors associated with morbidity following SNS for FI. <h3>Method</h3> An IRB approved retrospective review of prospectively collected data of patients treated for FI with SNS was performed. Demographic variables, causes of FI and surgical details were correlated with the incidence of morbidity. Morbidity included pain, infection, noninfectious wound concerns, lead-related issues, loss and lack of efficacy. Categorical variables were analysed with Chi-squared analysis, whereas non-parametric variables were compared with the Mann Whitney U test. Significance was defined as a p-value less than 0.05. <h3>Results</h3> 115 patients (mean age 58.5 ± 15 years, 85% females) underwent implantation of the device from 2010 to 2014 in one institution. The median follow-up was 8 (range 0.3–37) months. The most common morbidity was stimulation related pain (21.7%) whereas pain at the site of implantation occurred in 11.3% of patients. Furthermore a history of pain syndromes (p = 0.03) was found to be significantly associated with higher rates of stimulation-related pain whereas the only factor associated with pain at the site of implantation was male gender (p = 0.01). A loss of efficacy was observed in 16.5% of patients while other 7% of patients never derived significant benefit. A loss of efficacy was found to be significantly associated with a prior spinal surgery (p = 0.03). 15% (17/115) underwent explantation after first surgery, and 8% (9/115) had surgical revision, with 33% (3/9) requiring further explantation. 13% (15/115) underwent reimplantation with 20% (3/15) requiring explantation. <h3>Conclusion</h3> There is minimal information on the rates of morbidity in patients with SNS procedures performed for FI. This study suggests that male gender, prior spinal surgery, and a history of pain syndromes were correlated with postoperative morbidity. <h3>Disclosure of interest</h3> None Declared.
SAT0037 An ENPP1-Specific Inhibitor Attenuates Extracellular Ecto-Pyrophosphatase Activity in Human Osteoarthritic Cartilage
Authors: U. Arad, S. Svetitsky, S. Journo, O. Danino, B. Fischer
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Calcium pyrophosphate deposition (CPPD) is associated with osteoarthritis (OA) and is the cause of a common inflammatory articular disease (1). Nucleotide pyrophosphatase/phosphodiesterase1 (eNPP1) is the major ecto-pyrophosphatase (NTPPPH) in chondrocytes and chondrocyte-derived matrix vesicles (MVs) (2). Thus, eNPP1 is a principle contributor to extracellular pyrophosphate levels and a potential target for interventions aimed at preventing CPPD. Recently, we synthesized and described a novel eNPP1 inhibitor (3). <h3>Objectives</h3> To evaluate whether the eNPP1-specific inhibitor, SK4A, attenuates NTPPPH activity in human OA articular cartilage. <h3>Methods</h3> Cartilage tissue, primary chondrocytes and cartilage-derived MVs were obtained from donors with osteoarthritis undergoing knee replacement surgery.The effect of SK4A on cell viability was assayed by the XTT method. eNPP1 expression was evaluated by Western blot. NTPPPH activity was measured by a colorimetric assay with thymidine 59-monophosphate p-nitrophenyl ester as a substrate and by HPLC analysis of ATP levels. <h3>Results</h3> Primary OA chondrocytes express eNPP1 in early passages, but this expression is subsequently lost upon further passaging. Similarly, significant NTPPPH activity can only be detected in early-passage human chondrocytes. The eNPP1 inhibitor, SK4A, does not affect chondrocyte viability at concentrations of up to 1mM. SK4A effectively inhibits the ex vivo NTPPPH activity in whole cartilage tissue, in isolated primary chondrocytes and in cartilage-derived MVs. <h3>Conclusions</h3> SK4A inhibits NTTTPH activity in human OA cartilage and may prevent extracellular pyrophosphate accumulation and calcium pyrophosphate deposition. <h3>References</h3> Zhang W, Doherty M, Bardin T, et al. Ann Rheum Dis. 2011;70(4):563-70. Johnson K, Terkeltaub R. Front Biosci. 2005; 10:988-97. Nadel Y, Lecka J, Gilad Y, et al. J Med Chem. 2014; 57(11): 4677-91. <h3>Disclosure of Interest</h3> None declared
Studies on the Anemia of Tumor-Bearing Animals. I. Distribution of Radioiron Following the Injection of Labeled Erythrocytes
Authors: Greenfield, Robert E., Godfrey, Jamie E., Price, Vincent E.
Journal: JNCI Journal of the National Cancer Institute (1958)

Journal Article Studies on the Anemia of Tumor-Bearing Animals. I. Distribution of Radioiron Following the Injection of Labeled Erythrocytes Get access Robert E. Greenfield, Robert E. Greenfield Laboratory of Biochemistry, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Jamie E. Godfrey, Jamie E. Godfrey Laboratory of Biochemistry, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Vincent E. Price Vincent E. Price Laboratory of Biochemistry, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 21, Issue 4, October 1958, Pages 641–656, https://doi.org/10.1093/jnci/21.4.641 Published: 01 October 1958 Article history Received: 29 April 1958 Published: 01 October 1958
Shellfish consumption and awareness of risk of acquiring hepatitis A among Neapolitan families - Italy 1997
Authors: G Salamina, P D'Argenio
Journal: Eurosurveillance (1998)

In 1996, about 15% of all reported cases of hepatitis A (n=8651) in Italy were from the Campania region, with Naples reporting the region s highest incidence (34.9/100 000). Almost a half of all cases were between 15 and 24 years of age. In recent years,
PWE-311 Extra-levator abdomino-perineal resection for low rectal cancer
Authors: E Tudor, Z Oliphant, M Marshall, C Worrall, P Mackey, L Hunt, T Edwards
Journal: Gut (2015)

<h3>Introduction</h3> Extra-levator abdomino-perineal resection (eLAP) has superseded standard abdomino-perineal excision (APER) for low rectal cancer. Reduction in rates of circumferential resection margin (CRM) involvement and tumour perforation offer improved oncological outcome. There is no consensus regarding management of the larger perineal defect that results. We report outcomes following primary closure following an eLAP. <h3>Method</h3> All eLAPs undertaken in a single centre over five years were identified. eLAP and primary closure is the local standard of care. A retrospective review recorded CRM involvement, primary wound healing and infection rates, the incidence of perineal herniae, and subsequent intervention if required. <h3>Results</h3> Fifty-one patients were identified, with a mean age of 70.2, and a male preponderance of 63%. Ten patients were classified ASA 3 (19.6%); the remainder were ASA 1–2. Thirty-two patients had a laparoscopic operation (63%), with a further 6 converted to open (12%). 14 patients had an open operation (27%). 38/51 patients (75%) had a clear CRM. There were no tumour perforations. EMVI was present in 13 patients (25%). Wound healing problems were identified in 12 patients (24%), with 6 requiring intervention (12%). The incidence of perineal hernia was 9/51 (18%) of which 5 (9.8%) were repaired surgically. <h3>Conclusion</h3> This series suggests that eLAP combined with primary closure of the perineum may offer the benefits of low rates of CRM involvement and tumour perforation yet minimal perineal wound related morbidity compared to published data. <h3>Disclosure of interest</h3> None Declared.
A family-based genome-wide association study reveals an association of spondyloarthritis with<i>MAPK14</i>
Authors: Félicie Costantino, Alice Talpin, Roula Said-Nahal, Ariane Leboime, Elena Zinovieva, Diana Zelenika, Ivo Gut, Céline Charon, Brigitte Izac, Michael Weissman, Gilles Chiocchia, John Reveille, Maxime Breban, Henri-Jean Garchon
Journal: Annals of the Rheumatic Diseases (2016)

Objective More than 40 loci have been associated with ankylosing spondylitis (AS), but less is known about genetic associations in spondyloarthritis (SpA) as a whole. We conducted a family-based genome-wide association study (GWAS) to identify new non-major histocompatibility complex (MHC) genetic factors associated with SpA. Methods 906 subjects from 156 French multiplex families, including 438 with SpA, were genotyped using Affymetrix 250K microarrays. Association was tested with Unphased. The best-associated non-MHC single nucleotide polymorphisms (SNPs) were then genotyped in two independent familial cohorts (including 215 French and 294 North American patients with SpA, respectively) to replicate associations. Results 43 non-MHC SNPs yielded an association signal with SpA in the discovery cohort (p&lt;1×10 −4 ). In the extension studies, association was replicated at a nominal p value of p&lt;0.05 for 16 SNPs in the second cohort and for three SNPs in the third cohort. Combined analysis identified an association close to genome-wide significance between rs7761118, an intronic SNP of MAPK14 , and SpA (p=3.5×10 −7 ). Such association appeared to be independent of HLA-B27. Conclusions We report here for the first time a family-based GWAS study on SpA and identified an associated polymorphism near MAPK14 . Further analyses are needed to better understand the functional basis of this genetic association.
Behavioral Counseling in Primary Care To Promote Physical Activity: Recommendation and Rationale
Journal: Annals of Internal Medicine (2002)

This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on counseling by primary care physicians to promote physical activity and the supporting scientific evidence, and it updates the 1996 recommendations contained in the Guide to Clinical Preventive Services, second edition. The complete USPSTF recommendations and rationale statement on this topic, which includes a brief review of the supporting evidence, is available through the USPSTF Web site (www.preventiveservices.ahrq.gov), the National Guideline Clearinghouse (www.guideline.gov), and in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295; e-mail, ahrqpubs@ahrq.gov). The complete information on which this statement is based, including tables and references, is available in the accompanying article in this issue and in the summary of the evidence and systematic evidence review on the Web sites already mentioned. *For a list of the members of the U.S. Preventive Services Task Force, see the Appendix.
Congenital neck masses
Authors: A J Drumm, J M Chow
Journal: BMJ (2010)

Neck masses are frequently encountered in children. Although they are most often due to past infections, they may be of congenital origin. A neck mass in an adult may also be benign and of congenital origin. Common congenital neck masses include thyroglossal duct cysts, branchial anomalies, cystic hygromas and hemangiomas. Cysts, sinuses and fistulas may arise from the branchial apparatus.
Detection of a Foreign Body during Laparoscopy for Differential Diagnosis in a Patient with Ascites
Authors: K Tuncer, U S Akarca, E O Aktaş, T Ilter, A Musoğlu
Journal: Endoscopy (2004)

A 67-year-old woman was admitted to the emergency department with complaints of abdominal pain and distension for 20 days. She had not previously undergone surgery or suffered any accident. Abdominal ascites was detected. The ascites was exudative (leukocytes 2000/mm3, lactate dehydrogenase (LDH) 6060 U/L and glucose 0 mg/dL), and the patient was therefore transferred to our clinic. Streptococcus pyogenes grew in the ascites culture after a few days
The Family
Authors: M Therese Southgate
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lessons Learned: Dose Selection of Small Molecule–Targeted Oncology Drugs
Authors: Julie M. Bullock, Atiqur Rahman, Qi Liu
Journal: Clinical Cancer Research (2016)

Evaluation of dose plays a critical role in a successful oncology development program. Typically for oncology agents, the first-in-man phase I dose-escalation trials are conducted to determine a maximum tolerated dose (MTD). This MTD is taken forward into subsequent trials to establish the safety and efficacy of the drug product. Although this approach was appropriate historically for cytotoxics, the application of MTD as the recommend phase II dose has been problematic for the newer small molecule-targeted oncology agents. Promising alternative approaches using dose and exposure exploration, including lessons learned from recent targeted oncology agent development and approvals, are summarized and discussed. Clin Cancer Res; 22(11); 2630-8. ©2016 AACR SEE ALL ARTICLES IN THIS CCR FOCUS SECTION, "NEW APPROACHES FOR OPTIMIZING DOSING OF ANTICANCER AGENTS".
PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status
Authors: Susanne Lütje, Sandra Heskamp, Alexander S. Cornelissen, Thorsten D. Poeppel, Sebastiaan A. M. W. van den Broek, Sandra Rosenbaum-Krumme, Andreas Bockisch, Martin Gotthardt, Mark Rijpkema, Otto C. Boerman
Journal: Theranostics (2015)

Prostate cancer (PCa) is the most common malignancy in men worldwide, leading to substantial morbidity and mortality. At present, imaging of PCa has become increasingly important for staging, restaging, and treatment selection. Until recently, choline-based positron emission tomography/computed tomography (PET/CT) represented the state-of-the-art radionuclide imaging technique for these purposes. However, its application is limited to patients with high PSA levels and Gleason scores. Prostate-specific membrane antigen (PSMA) is a promising new target for specific imaging of PCa, because it is upregulated in the majority of PCa. Moreover, PSMA can serve as a target for therapeutic applications. Currently, several small-molecule PSMA ligands with excellent in vivo tumor targeting characteristics are being investigated for their potential in theranostic applications in PCa. Here, a review of the recent developments in PSMA-based diagnostic imaging and therapy in patients with PCa with radiolabeled PSMA ligands is provided.
Patient Navigation for Comprehensive Cancer Screening in High-Risk Patients Using a Population-Based Health Information Technology System
Authors: Sanja Percac-Lima, Jeffrey M. Ashburner, Adrian H. Zai, Yuchiao Chang, Sarah A. Oo, Erica Guimaraes, Steven J. Atlas
Journal: JAMA Internal Medicine (2016)

Patient navigation (PN) to improve cancer screening in low-income and racial/ethnic minority populations usually focuses on navigating for single cancers in community health center settings.We evaluated PN for breast, cervical, and colorectal cancer screening using a population-based information technology (IT) system within a primary care network.Randomized clinical trial conducted from April 2014 to December 2014 in 18 practices in an academic primary care network. All patients eligible and overdue for cancer screening were identified and managed using a population-based IT system. Those at high risk for nonadherence with completing screening were identified using an electronic algorithm (language spoken, number of overdue tests, no-show visit history), and randomized to a PN intervention (n = 792) or usual care (n = 820). Navigators used the IT system to track patients, contact them, and provide intense outreach to help them complete cancer screening.Mean cancer screening test completion rate over 8-month trial for each eligible patient, with all overdue cancer screening tests combined using linear regression models. Secondary outcomes included the proportion of patients completing any and each overdue cancer screening test.Among 1612 patients (673 men and 975 women; median age, 57 years), baseline patient characteristics were similar among randomized groups. Of 792 intervention patients, patient navigators were unable to reach 151 (19%), deferred 246 (38%) (eg, patient declined, competing comorbidity), and navigated 202 (32%). The mean proportion of patients who were up to date with screening among all overdue screening examinations was higher in the intervention vs the control group for all cancers combined (10.2% vs 6.8%; 95% CI [for the difference], 1.5%-5.2%; P < .001), and for breast (14.7% vs 11.0%; 95% CI, 0.2%-7.3%; P = .04), cervical (11.1% vs 5.7%; 95% CI, 0.8%-5.2%; P = .002), and colon (7.6% vs 4.6%; 95% CI, 0.8%-5.2%; P = .01) cancer compared with control. The proportion of overdue patients who completed any cancer screening during follow-up was higher in the intervention group (25.5% vs 17.0%; 95% CI, 4.7%-12.7%; P < .001). The intervention group had more patients completing screening for breast (23.4% vs 16.6%; 95% CI, 1.8%-12.0%; P = .009), cervical (14.4% vs 8.6%; 95% CI, 1.6%-10.5%; P = .007), and colorectal (13.7% vs 7.0%; 95% CI, 3.2%-10.4%; P < .001) cancer.Patient navigation as part of a population-based IT system significantly increased screening rates for breast, cervical, and colorectal cancer in patients at high risk for nonadherence with testing. Integrating patient navigation into population health management activities for low-income and racial/ethnic minority patients might improve equity of cancer care.clinicaltrials.gov Identifier: NCT02553538.
BRCA mutations and survival in breast cancer.
Authors: W D Foulkes, N Wong, J S Brunet, S A Narod
Journal: Journal of Clinical Oncology (1998)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1998.16.9.3206 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9738598 BRCA mutations and survival in breast cancer. W D FoulkesxW D FoulkesSearch for articles by this author , N WongxN WongSearch for articles by this author , J S BrunetxJ S BrunetSearch for articles by this author , S A NarodxS A NarodSearch for articles by this author https://doi.org/10.1200/JCO.1998.16.9.3206 First Page PDF © 1998 by American Society of Clinical Oncology
Alexithymia in panic disorder and simple phobia: a comparative study
Authors: J D Parker, G J Taylor, R M Bagby, M W Acklin
Journal: American Journal of Psychiatry (1993)

The authors found that 14 (46.7%) of 30 patients with panic disorder had alexithymia, compared with four (12.5%) of 32 patients with simple phobia. Consistent with the conceptualization of alexithymia as a psychological deficit affecting emotion regulation, the patients with panic disorder had significantly less ego strength and independence and significantly higher levels of anxiety and somatic complaints than the patients with simple phobia.